Research has shown that AGG interruption analysis can help us provide you and your patients who are found to be fragile X premutation carriers with a more refined reproductive risk. [1, 2] 

A higher number of AGG interruptions is associated with a lower risk of expansion. By counting the number of AGG repeats present, we can help refine the risk of a woman having a child affected with fragile X syndrome. [1, 2]

Counsyl is excited to announce that we are now offering AGG interruption analysis for select fragile X orders. [3]


Graph adapted from:

Applicable to ~1 in 200 women tested:* 

1. Patients identified with 55-90 CGG repeats for fragile X syndrome will automatically receive AGG interruption analysis via Asuragen. There will be no additional charge for this feature.

2. A preliminary Foresight™ Carrier Screen report will be issued within the normal two week turnaround time with Fragile X CGG repeat results and an final report will be issued within 3 weeks of the preliminary report with the results of the AGG interruption analysis.

3. AGG interruption analysis can not be performed on saliva samples. If a saliva sample returns with 55-90 CGG repeats, a secondary blood collection kit will be sent to your clinic in order to complete AGG analysis.

*Based on internal data

An updated informed consent form is necessary to cover this analysis. Log into to access this updated form.

Note: AGG interruption analysis is not available for international orders

Questions? Contact [email protected] or reach out directly to your Counsyl representative.

Illuminating the path to better health through genetic insights

Our tests and screens reveal information to guide patients and providers to better health and well-being. Whether you’re searching for answers related to cancer risk, cancer treatment, prenatal care or mental health, Myriad screens and tests can help.